Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Post by fouremmon Jun 27, 2013 12:32pm
686 Views
Post# 21576616

The long Halt

The long HaltGiven that it has been over 3 hours since the halt was announced I'm thinking we are awaiting good news because if the news were bad it would be a very straight forward news release.  

Good news could be more complicated however as the release of good news could prompt wild speculation as to what RVX might be worth, something which the TSX tries to discourage .  What might control speculation would be if there was a simultaneous release of a deal for RVX.   DM has said previously that more than one pharma had completed their due diligence and were just awaiting results just as we are.  Assuming the halt is due to the pending release of results, RVX has now taken care of the it's regulatory obligations wrt the fact there is material news and it could be that DM is now discussing deals with interested pharma.  In my opinion the longer the halt  the better news to a degree.  If the news is good it would stand to reason that the better the news the greater the number of interested pharma and the longer the deal process would be.

If the news is very good I wouldn't be suprised if the halt lasted the rest of the day or perhaps longer.

All just my opinion 
Bullboard Posts